Could a common drug change how opioids work in the body?

NCT ID NCT06585163

Completed Knowledge-focused Sponsor: Quivive Pharma, Inc. Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This early-stage trial is testing whether an experimental oral suspension called QEV-817 (doxapram) changes how the body handles the opioid hydrocodone. Healthy volunteers aged 18-55 will receive hydrocodone with and without doxapram to compare safety and drug levels in the blood. The goal is to understand potential interactions and gather initial safety data.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: doxapram hydrochloride (QEV-817) oral suspension, given with and without hydrocodone bitartrate
What this could lead to: If doxapram safely changes how hydrocodone is processed, it might help reduce opioid side effects or improve pain management strategies.
What could go wrong: This is a very early, small study in healthy volunteers, not patients. Results may not apply to real-world use, and safety or drug interactions could differ.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PK DRUG-DRUG INTERACTION STUDY

Contacts and locations

Locations

Frontage Clinical Services, Inc.

Secaucus, New Jersey, 07094, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.